The Capital Markets and Women’s Health + Wellness teams advised the underwriters in the successful closing of the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY). Femasys offered 2,650,000 shares of its common stock at a public price of $13.00 per share. In addition, Femasys granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. Chardan acted as lead left bookrunner for the offering. JonesTrading Institutional Services, LLC also acted as a bookrunner for the offering.
Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment.
The Goodwin team was led by Thomas Levato, Kristopher Brown, Kaitlin Carragher, and Stephanie Barbanell (Corporate), and included Julie Tibbets (FDA Regulatory); Simone Otenaike, and Heath Ingram (Healthcare); Martin Gomez, Ken Radcliffe, Olivia Uitto, Leon Peschel (Tax); Grace Wirth (ERISA and Exec Comp); Tim Worden and Lucy Sharples (U.K. Regulatory); and Peter LaVigne (FINRA); with invaluable assistance from Nathan Needle.
For more details, read the press release and articles in Femtech Insider, Market Watch, and Puget Sound Busines Journal.
Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment.
The Goodwin team was led by Thomas Levato, Kristopher Brown, Kaitlin Carragher, and Stephanie Barbanell (Corporate), and included Julie Tibbets (FDA Regulatory); Simone Otenaike, and Heath Ingram (Healthcare); Martin Gomez, Ken Radcliffe, Olivia Uitto, Leon Peschel (Tax); Grace Wirth (ERISA and Exec Comp); Tim Worden and Lucy Sharples (U.K. Regulatory); and Peter LaVigne (FINRA); with invaluable assistance from Nathan Needle.
For more details, read the press release and articles in Femtech Insider, Market Watch, and Puget Sound Busines Journal.